» Articles » PMID: 20816192

Prediction of the Incidence, Recurrence, and Persistence of Atopic Dermatitis in Adolescence: a Prospective Cohort Study

Overview
Date 2010 Sep 7
PMID 20816192
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although it is known that atopic dermatitis (AD) can develop during adolescence, research on its course and predictors in this age group is thus far limited.

Objective: We aimed to describe the course of AD over puberty and prospectively determine risk factors for the incidence, recurrence, and persistence of AD until adolescence in a population-based cohort study.

Methods: German participants of the International Study of Asthma and Allergies in Childhood Phase II were followed prospectively. The final dataset comprised 2857 adolescents, of whom 2433 were unaffected by AD at baseline. Bivariate and multivariate prediction models for the incidence, recurrence, and persistence of AD using early-life factors, family history of atopic diseases, and job history as predictors were developed.

Results: The incidence of AD between ages 9 to 11 and 16 to 20 years was 1.7%, and recurrence was 2.4%. AD persisted in 47.6% of adolescents with AD symptoms at baseline (n = 424). High socioeconomic status, female sex, asthma symptoms and a positive skin prick test response at baseline, parental history of rhinitis/AD, and having worked in a high-risk job were significant predictors for the course of disease. With all the factors present, the probability of the incidence of AD was 21.4% (95% CI, 1.8% to 80.2%) and increased up to 81.7% (95% CI, 47.0% to 95.8%) for recurrence of AD and 87.6% (95% CI, 63.4% to 96.6%) for persistence of AD among those affected by AD. Early-life exposures did not predict the course of AD over puberty.

Conclusion: Genetic factors, early allergen sensitization, and having worked in a high-risk job seem to be more important for disease development in late adolescence than other early-life exposures.

Citing Articles

Disease modification in inflammatory skin disorders: opportunities and challenges.

Bieber T Nat Rev Drug Discov. 2023; 22(8):662-680.

PMID: 37443275 DOI: 10.1038/s41573-023-00735-0.


Atopic Dermatitis: Disease Features, Therapeutic Options, and a Multidisciplinary Approach.

Lugovic-Mihic L, Mestrovic-Stefekov J, Potocnjak I, Cindric T, Ilic I, Lovric I Life (Basel). 2023; 13(6).

PMID: 37374201 PMC: 10305021. DOI: 10.3390/life13061419.


Epidemiology of adult patients with atopic dermatitis in AWARE 1: A second international survey.

Maspero J, de Paula Motta Rubini N, Zhang J, Sanclemente G, Amador J, El Sayed M World Allergy Organ J. 2023; 16(3):100724.

PMID: 37033301 PMC: 10074250. DOI: 10.1016/j.waojou.2022.100724.


Antibody-Mediated Delivery of VEGF-C Promotes Long-Lasting Lymphatic Expansion That Reduces Recurrent Inflammation.

Cousin N, Bartel S, Scholl J, Tacconi C, Egger A, Thorhallsdottir G Cells. 2023; 12(1).

PMID: 36611965 PMC: 9818868. DOI: 10.3390/cells12010172.


Lindley Administration Attenuates Atopic Dermatitis-like Lesions by Modulating Immune Cells.

Hong S, Kim E, Lim S, Kim J, Sohn Y, Jung H Int J Mol Sci. 2022; 23(8).

PMID: 35457288 PMC: 9030638. DOI: 10.3390/ijms23084470.